Successful treatment of chronic hepatitis B and D with pegylated-interferon plus entecavir

Successful treatment of chronic hepatitis B and D with pegylated-interferon plus entecavir

Interferon-based regimen has been used to treat hepatitis D virus (HDV) super-infection on top of hepatitis B virus (HBV) carriers; however, viral relapse is frequent after stopping therapy. Recently, quantitative hepatitis B surface antigen (qHBsAg) was introduced to help the management of chronic...

Full description

Bibliographic Details
Main Authors:	Guei-Ying Chen, Tung-Hung Su, Jia-Horng Kao
Format:	Article
Language:	English
Published:	Elsevier 2015-11-01
Series:	Journal of the Formosan Medical Association
Subjects:	hepatitis B surface antigen HBsAg liver fibrosis regression combination therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S0929664613001782

Similar Items

Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients
by: Yan L, et al.
Published: (2018-10-01)

Hepatitis B virus surface antigen seroconversion in HIV-infected individual after pegylated interferon-alpha treatment: a case report
by: Adriane Maira Delicio, et al.
Published: (2013-12-01)

Response predictors to treatment with pegylated interferon in chronic hepatitis B
by: Paulo Roberto Abrão Ferreira, et al.

Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy
by: Kanako Yoshida, et al.
Published: (2021-02-01)

Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon
by: Hong Li, et al.
Published: (2022-12-01)

Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies
by: Lorenzo Piermatteo, et al.
Published: (2023-12-01)

Age-wise and Gender-wise Prevalence of Hepatitis B Virus (HBV) Infection in Lahore, Pakistan
by: Aqib Nazeer, et al.
Published: (2019-12-01)

Analytical Performance of the Sysmex HISCL HBsAg Assay and Comparison with the Roche Elecsys HBsAg II Quant Assay in the Quantification of Hepatitis B Surface Antigen
by: Joonhong Park, et al.
Published: (2021-11-01)

Seroprevalence of hepatitis B surface antigen and its correlation with risk factors among new recruits in Turkey
by: Tulin Altay, et al.

Low Level of Serum Immunoglobulin G Is Beneficial to Clinical Cure Obtained With Pegylated Interferon Therapy in Inactive Surface Antigen Carriers
by: Hong Li, et al.
Published: (2022-04-01)

Accuracy Validation of the Elecsys HBsAg II Quant Assay and Its Utility in Resolving Equivocal Qualitative HBsAg Results
by: Jaehyeon Lee, et al.
Published: (2023-02-01)

A comparison on HBsAg and HBsAb prevalence in patients with Down syndrome and other mentally retarded patients living in retarded children institutes in Tehran
by: Sahebjamei M. Associate Professor, et al.
Published: (2003-06-01)

Seroprevalence of Hepatitis B virus Infection by Quantitative Chemiluminescent in Tabriz (North West of Iran), 2010-2011
by: Nader Hajizadeh, et al.
Published: (2014-08-01)

Prediction for HBsAg seroconversion in children with chronic hepatitis B
by: Yan-Wei Zhong, et al.
Published: (2021-12-01)

Seromarkers of Hepatitis B virus in newborns with HBsAg positive mothers
by: Yousef Yahyapour (PhD), et al.
Published: (2009-05-01)

Clinical outcomes of treatment-naïve HBeAg-negative patients with chronic hepatitis B virus infection with low serum HBsAg and undetectable HBV DNA
by: Jian Wang, et al.
Published: (2024-12-01)

Performance Evaluation of an Improved HBsAg Assay (HBsAg NEXT) for the Detection of HBsAg Levels
by: Ekta Gupta, et al.
Published: (2023-12-01)

Occult hepatitis B virus infection: clearance or disguise?
by: Jin-Wook Kim
Published: (2014-09-01)

HBsAg in Cord Blood Qf Newborns of HBsAg-Positive Mothers
by: Adnan S. Wiharta, et al.
Published: (2018-11-01)

Kinetics in HBsAg after Stopping Entecavir or Tenofovir in Patients with Virological Relapse but Not Clinical Relapse
by: Tzu-Ning Tseng, et al.
Published: (2022-05-01)

Comparative ELISA reagents for detection of hepatitis B surface antigen (HBsAg) Comparação de reativos para o teste de ELISA na evidenciação do antígeno de superfície de hepatite B
by: I. F. Camargo, et al.
Published: (1987-06-01)

Sero-prevalence of Hepatitis B Virus infection in Balochistan province of Pakistan
by: Nadeem S Sheikh, et al.
Published: (2011-01-01)

Evolution of hepatitis B virus surface gene and protein among Iranian chronic carriers from different provinces
by: Fatemeh Ramezani, et al.
Published: (2015-11-01)

Distinct patterns of serum hepatitis B core-related antigen during the natural history of chronic hepatitis B
by: Zhan-Qing Zhang, et al.
Published: (2017-12-01)

Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-neegative chronic hepatitis B: A multicentre cohort study
by: Milan J. Sonneveld, et al.
Published: (2023-08-01)

Evaluación serológica de la inmunización pasiva-activa en la profilaxis de la transmisión perinatal de la hepatitis B
by: Marité Bello, et al.
Published: (2012-04-01)

Evaluating the Immunity against Hepatitis B Virus and Frequency of HBsAg Positive Cases among Medical Staff of Shahid Beheshti Hospital in Yasuj, 2016
by: MT Rezanejad, et al.
Published: (2017-12-01)

Prevalencia de anticuerpos anti-VHC y del antígeno de superficie de la hepatitis B en pacientes tratados con hemodiálisis Prevalence of anti-HCV antibodies and of the hepatitis B surface antigen in patients treated with hemodialysis
by: Zuzet Martínez Córdova, et al.
Published: (2008-03-01)

Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study
by: Fumitaka Suzuki, et al.
Published: (2021-12-01)

Clinical Outcomes and Quantitative HBV Surface Antigen Levels in Diverse Chronic Hepatitis B Patients in Canada: A Retrospective Real-World Study of CHB in Canada (REVEAL-CANADA)
by: Carla S. Coffin, et al.
Published: (2022-11-01)

Kinetics of Hepatitis B Virus Load During Haemodialysis Sessions and α-Interferon: A Prospective Study
by: Fabrizio Fabrizi, et al.
Published: (2013-09-01)

Clinical cure induced by pegylated interferon α-2b in the advantaged population of chronic hepatitis B virus infection: a retrospective cohort study
by: Chaojing Wen, et al.
Published: (2024-01-01)

RNA Interference Therapy for Chronic Hepatitis B Predicts the Importance of Addressing Viral Integration When Developing Novel Cure Strategies
by: Christine I. Wooddell, et al.
Published: (2021-03-01)

Long-Term HBsAg Titer Kinetics with Entecavir/Tenofovir: Implications for Predicting Functional Cure and Low Levels
by: Soon Kyu Lee, et al.
Published: (2024-02-01)

Epidemiology of Chronic Hepatitis B Infection in the Cohort of College Students with Vaccination in Taiwan
by: Te-Wei Cheng, et al.
Published: (2023-02-01)

Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B
by: Li H, et al.
Published: (2018-05-01)

New perspectives of biomarkers for the management of chronic hepatitis B
by: Chih-Lin Lin, et al.
Published: (2016-12-01)

Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection
by: Romina Salpini, et al.
Published: (2020-01-01)

Assessing risk of liver enzyme elevation in patients with immune-mediated diseases and different hepatitis B virus serostatus receiving anti-TNF agents: a nested case-control study
by: Ying-Ming Chiu, et al.
Published: (2017-11-01)

Geographic distribution of HBsAg subtypes in Brazil Distribuição geográfica dos subtipos de antígenos de HBsAg no Brasil
by: Ana Maria Coimbra Gaspar, et al.
Published: (1987-06-01)